BioSpace News Archive

- Positive CRV431 Data in Models of Acute Pulmonary Injury and SARS-CoV-2 Viral Replication - CRV431 attenuated lung inflammation and damage similar to or better than dexamethasone, including reductions in neutrophils and IL-6 CRV431 decreased SARS-CoV-2 replication and production of infectious virus in vitro CRV431 may offer opportunity to treat both viral infection and lung inflammation in COVID-19 EDISON, NJ / ACCESSWIRE / July 7, 2020 / Hepion Pharmaceuticals, Inc.

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the completion of patient enrollment in its NORSE 2 clinical trial for ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for use in retinal indications.

The Company also reports that all preferred shares and warrants outstanding have been exercised, establishing a cash balance of approximately $6 Million as of June 30, 2020

- Happiness Biotech Group Limited (the “Company” or Nasdaq: HAPP), an innovative China -based nutraceutical and dietary supplements producer, announced today that the 75% Alcohol Disposable Hand Sanitizer from the Company has successfully obtained Natural Product Number (NPN) license from Health Canada and the first order of 53,280

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or the “Company”) announces it has engaged Pro Football Hall of Fame and College Football Hall of Fame inductee Mike Haynes as an advisor to the Company and as spokesman for Qualigen’s FastPack ® rapid diagnostic system. After receiving an elevated PSA test result using a F

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2020 financial results on Tuesday, July 28, 2020. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, July 28, 2020 to discuss its second quarter 2020 financial results. The call may be accessed throug

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the appointment of Thomas F. Gajewski, M.D., Ph.D., and Stephan Grupp, M.D., Ph.D. to its Scientific Advisory Board (SAB). The SAB comprises experts across oncology, immunology, cell therapy, and drug discovery and development. “We are privileged to we

Cerus Corporation (Nasdaq:CERS) announced today study results demonstrating that the INTERCEPT Blood System inactivates SARS-CoV-2, the causative agent for COVID-19, in plasma components intended for transfusion. These data are consistent with prior INTERCEPT studies showing complete inactivation, to below the limit of detection, of other coronaviruses associated with severe pulmonary disease: MERS-CoV 1,2 (2018, 2019) a

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX ), a clinical-stage biomedical company, provides the following update regarding upcoming news in its Dry Eye Disease Program. Dry Eye Disease (DED) – ProtoKinetix is expecting closure of agreements for the first steps in a roll-out of a new product line development that will

Kenergy Scientific Inc. is pleased to announce it has executed a Share Exchange agreement with “KNSC” and Florida based MedSmart Group, Inc. KNSC has acquired all of the issued and outstanding shares of MedSmart Group Inc. a Florida based medical wellness and antiaging centers focused on Men’s health.